At the 2025 Alzheimer’s Association International Conference (AAIC), one of the bigger splashes was made by a cardiovascular drug. In a presentation on Newamsterdam Pharma Co. NV presented data ...

Around 10 million people globally live with the life-threatening human T-cell lymphotropic virus type-1 (HTLV-1), yet it ...

Radiopharm Theranostics Ltd. announced that the U.S. FDA has cleared the IND application for betabart (RV-01), its Lu177-B7H3 ...

The approval to reduce proteinuria for those 12 and older with either of the two severe and rare kidney diseases came on the July 28 PDUFA date, a little more than four years after the company won ...

Med-tech companies raised $8.13 billion in the second quarter of 2025, a modest dip from the $8.32 billion recorded in Q1. While the quarterly total marks a continued improvement over 2023’s lower ...

Total venture capital funding in U.K. biotech was £1.23 billion (US$1.64 billion) in the first half of 2025, almost matching ...

Osteoporosis involves degradation of bone throughout the body, and it already affects nearly a quarter of a billion people in ...

Boston Scientific Corp. received CE mark certification under the Medical Device Regulation for its Intracept intraosseous ...

Centauri Therapeutics Ltd. and Kinvard Bio Inc. have separately announced new funding from CARB-X (Combating ...

Sarepta Therapeutics Inc.’s adventure with the Duchenne muscular dystrophy (DMD) AAV-based gene therapy Elevidys (delandistrogene moxeparvovec) continued as the firm said it would restart shipments of ...

People with the subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) associated with fusion of MEF2D with other genes show quite poor prognosis. Most patients fail to respond to ...

PTC Therapeutics Inc. will be launching its oral phenylketonuria therapy, Sephience (sepiapterin) in both the U.S. and Europe this summer, following the U.S. FDA approval just ahead of its July 29 ...